Sam blends considerable international legal experience with expertise in the biotechnology and molecular biology fields.
Sam works for clients ranging from universities and spin-out companies to large international corporations. He has a particular interest in biopharmaceuticals, including engineered antibodies, antibody-drug conjugates, and immuno-oncology, as well as medical devices.
He has extensive experience in advising on patentability and freedom-to-operate issues, filing strategies, and the drafting and prosecution of local and international patent applications in the bioscience and biomedical fields. He has also advised on patent term extensions and supplementary protection certificates for pharmaceuticals in Europe and elsewhere.
Sam conducted his masters research in embryology in the Reproductive Technologies Group of the Crown Research Institute AgResearch, and went on to conduct further research in the Group. During this time, he developed broad experience in assisted reproductive technologies, sub-cloning, mammalian cell culture, epigenetics, and recombinant protein production. Sam joined the patent profession in New Zealand in 2001, and then spent 12 years working in Europe as a Chartered UK and European patent attorney, before returning to AJ Park in 2019.
Sam's experience working as a qualified attorney in New Zealand and Australia, together with his experience of European and UK practice, provides him with a strong international perspective on patent drafting and prosecution. As a reflection of this, in 2016, Sam was chosen to be a member of one of the examination committees that sets and assesses the European qualification examination for candidates wishing to become professional representatives before the European Patent Office.
- BSc (Biology & Chemistry), University of Waikato (1997)
- MSc (Hons) (Biology), University of Waikato (1999)
- Registered Patent Attorney (New Zealand & Australia)
- Chartered UK & European Patent Attorney
Sam Pearson's insights
Article \ 30 Jul 2021
Upcoming changes to make amends for Australian designs
The Australian Government are progressing a programme of reforms to ensure the Australian design rights system is fit for purpose and to…
Article \ 29 Apr 2021
Managing intangible assets for exponential growth
Intangible assets do not occupy physical space. However, they have the potential to provide high value and exponential growth when identified and…
Article \ 3 Dec 2020
Australian High Court rejects the implied licence doctrine: establishes exhaustion…
The High Court of Australia has recently passed down a landmark 4-3 majority decision in Calidad Pty Ltd v Seiko Epson Corporation…
Article \ 30 Nov 2020
Medicinal cannabis in New Zealand – a potted summary of…
The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 came into effect from 1 April 2020. These regulations establish a scheme for licencing…
Article \ 26 Nov 2020
Pesky pandemics and patents: how the conventional patent approach appears…
Over 70 vaccines and 150 drugs are currently being developed by various entities in an effort to combat the COVID-19 pandemic. Any…
Article \ 18 Nov 2020
Proposed changes to New Zealand intellectual property laws
The New Zealand Government has recently proposed several amendments to New Zealand’s intellectual property laws, including the Patents Act 2013 (PA), the…
Article \ 29 Oct 2020
How to strategically deploy an IP programme for success
Being strategic with your intellectual property (IP) can be really important. But what is often even more important, especially for businesses built…